AIROMIR METERED-DOSE AEROSOL

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

SALBUTAMOL (SALBUTAMOL SULFATE)

Disponible des:

BAUSCH HEALTH, CANADA INC.

Codi ATC:

R03AC02

Designació comuna internacional (DCI):

SALBUTAMOL

Dosis:

100MCG

formulario farmacéutico:

METERED-DOSE AEROSOL

Composición:

SALBUTAMOL (SALBUTAMOL SULFATE) 100MCG

Vía de administración:

INHALATION

Unidades en paquete:

100/200 DOSES

tipo de receta:

Prescription

Área terapéutica:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Resumen del producto:

Active ingredient group (AIG) number: 0108887003; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2012-01-04

Fitxa tècnica

_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AIROMIR
®
Salbutamol Inhalation Aerosol, Mfr. Std.
100 mcg salbutamol (as Salbutamol Sulfate) per actuation
BRONCHODILATOR
BETA
2
-ADRENERGIC AGONIST
BAUSCH HEALTH, CANADA INC.
2150 St-Elzear Blvd., West
Laval, Quebec H7L 4A8
Canada
DATE OF REVISION:
December 22, 2020
Submission Control No: 241784
_Pr_
_AIROMIR_
_®_
_ Product Monograph Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
......................................................